Jerry Y. Hsu

3.1k total citations · 1 hit paper
43 papers, 2.3k citations indexed

About

Jerry Y. Hsu is a scholar working on Molecular Biology, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Jerry Y. Hsu has authored 43 papers receiving a total of 2.3k indexed citations (citations by other indexed papers that have themselves been cited), including 24 papers in Molecular Biology, 23 papers in Oncology and 20 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Jerry Y. Hsu's work include PI3K/AKT/mTOR signaling in cancer (15 papers), Advanced Breast Cancer Therapies (12 papers) and Cancer Treatment and Pharmacology (11 papers). Jerry Y. Hsu is often cited by papers focused on PI3K/AKT/mTOR signaling in cancer (15 papers), Advanced Breast Cancer Therapies (12 papers) and Cancer Treatment and Pharmacology (11 papers). Jerry Y. Hsu collaborates with scholars based in United States, Spain and Canada. Jerry Y. Hsu's co-authors include Peter K. Jackson, Julie D.R. Reimann, Ellen Freed, Adam G. Eldridge, Brett K. Kaiser, Heather A. Wakelee, Jan‐Michael Peters, Claus Storgaard Sørensen, Edgar R. Kramer and Florence Margottin-Goguet and has published in prestigious journals such as Cell, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Jerry Y. Hsu

39 papers receiving 2.3k citations

Hit Papers

The lore of the RINGs: substrate recognition and catalysi... 2000 2026 2008 2017 2000 100 200 300 400 500
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. The lore of the RINGs: substrate recognition and catalysis by ubiquitin ligases
    2000 532 citations Peter K. Jackson, Adam G. Eldridge et al. Trends in Cell Biology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Jerry Y. Hsu United States 17 1.8k 777 723 373 208 43 2.3k
Frauke Schimmöller United States 17 1.2k 0.7× 980 1.3× 336 0.5× 386 1.0× 122 0.6× 35 1.9k
Grzegorz Nalepa United States 21 2.0k 1.2× 597 0.8× 724 1.0× 99 0.3× 264 1.3× 42 2.5k
Andrew Wilber United States 28 1.7k 0.9× 276 0.4× 895 1.2× 278 0.7× 170 0.8× 62 2.8k
Panayotis Zacharatos Greece 17 2.5k 1.5× 381 0.5× 1.2k 1.7× 169 0.5× 133 0.6× 21 3.1k
Sylvie Giuriato France 21 1.3k 0.7× 379 0.5× 388 0.5× 142 0.4× 157 0.8× 35 2.2k
Tsz Kan Fung Hong Kong 21 1.5k 0.8× 277 0.4× 506 0.7× 94 0.3× 84 0.4× 29 1.9k
Olle Sangfelt Sweden 31 2.3k 1.3× 505 0.6× 1.3k 1.8× 131 0.4× 295 1.4× 51 3.4k
Marc R. Mansour United Kingdom 26 1.9k 1.1× 264 0.3× 557 0.8× 118 0.3× 79 0.4× 59 2.9k
Yong Wan United States 26 1.6k 0.9× 366 0.5× 621 0.9× 159 0.4× 117 0.6× 45 2.2k
Matty Verlaan–de Vries Netherlands 17 1.7k 1.0× 192 0.2× 755 1.0× 172 0.5× 86 0.4× 24 2.2k

Countries citing papers authored by Jerry Y. Hsu

Since Specialization
Citations

This map shows the geographic impact of Jerry Y. Hsu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jerry Y. Hsu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jerry Y. Hsu more than expected).

Fields of papers citing papers by Jerry Y. Hsu

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jerry Y. Hsu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jerry Y. Hsu. The network helps show where Jerry Y. Hsu may publish in the future.

Co-authorship network of co-authors of Jerry Y. Hsu

This figure shows the co-authorship network connecting the top 25 collaborators of Jerry Y. Hsu. A scholar is included among the top collaborators of Jerry Y. Hsu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jerry Y. Hsu. Jerry Y. Hsu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Hsu, Jerry Y., et al.. (2025). Pseudophakic mini-monovision. Survey of Ophthalmology. 71(3). 973–979.
2.
Spira, Alexander I., Byoung Chul Cho, Enriqueta Felip, et al.. (2024). FURVENT: Phase 3 trial of firmonertinib vs chemotherapy as first-line treatment for advanced NSCLC with EGFR exon 20 insertion mutations (FURMO-004). Lung Cancer. 199. 108066–108066. 2 indexed citations
3.
Nilsson, Monique B., Zineb Mounir, Luna Musib, et al.. (2024). Abstract 1964: Furmonertinib is a brain-penetrant EGFR TKI highly active in uncommon EGFR mutations, including PACC and exon 20 insertions. Cancer Research. 84(6_Supplement). 1964–1964.
4.
Spira, Alexander I., Byoung Chul Cho, Enriqueta Felip, et al.. (2024). PP01.24 FURVENT: Phase 3 trial testing furmonertinib vs chemotherapy as first-line treatment for advanced NSCLC with EGFR exon 20 insertions (FURMO-004). Journal of Thoracic Oncology. 19(7). e17–e18.
5.
Barsoumian, Hampartsoum B., Jerry Y. Hsu, Yun Hu, et al.. (2023). The RadScopal Technique as an Immune Adjuvant to Treat Cancer. SHILAP Revista de lepidopterología. 3(1). 74–85. 3 indexed citations
6.
Hsu, Jerry Y., Jasmine H. Francis, & Sumayya Ahmad. (2023). Ocular toxicities of fibroblast growth factor receptor inhibitors: A review. Survey of Ophthalmology. 69(1). 34–41. 5 indexed citations
7.
Nelson, Jessica C., Kurt C. Marsden, Jerry Y. Hsu, et al.. (2021). A forward genetic screen identifies Dolk as a regulator of startle magnitude through the potassium channel subunit Kv1.1. PLoS Genetics. 17(6). e1008943–e1008943. 12 indexed citations
8.
Dent, Susan, Javier Cortés, Young‐Hyuck Im, et al.. (2020). Phase III randomized study of taselisib or placebo with fulvestrant in estrogen receptor-positive, PIK3CA-mutant, HER2-negative, advanced breast cancer: the SANDPIPER trial. Annals of Oncology. 32(2). 197–207. 116 indexed citations
9.
10.
Hsu, Jerry Y., et al.. (2020). Absorption and disposition kinetics of trimethoprim following intramuscular injection in rabbits. Journal of Food and Drug Analysis. 6(2). 1 indexed citations
11.
Dickler, Maura N., Cristina Saura, Donald Richards, et al.. (2018). Phase II Study of Taselisib (GDC-0032) in Combination with Fulvestrant in Patients with HER2-Negative, Hormone Receptor–Positive Advanced Breast Cancer. Clinical Cancer Research. 24(18). 4380–4387. 57 indexed citations
12.
13.
Juric, Dejan, Ian E. Krop, Ramesh K. Ramanathan, et al.. (2017). Phase I Dose-Escalation Study of Taselisib, an Oral PI3K Inhibitor, in Patients with Advanced Solid Tumors. Cancer Discovery. 7(7). 704–715. 120 indexed citations
14.
Hsu, Jerry Y. & Heather A. Wakelee. (2009). Monoclonal Antibodies Targeting Vascular Endothelial Growth Factor. BioDrugs. 23(5). 289–304. 115 indexed citations
15.
Hsu, Jerry Y. & Heather A. Wakelee. (2008). Pemetrexed disodium for the treatment of NSCLC: An update. Drugs of today. 44(9). 669–669. 2 indexed citations
16.
Lehman, Norman L., Emmy W. Verschuren, Jerry Y. Hsu, Athena M. Cherry, & Peter K. Jackson. (2006). Overexpression of the Anaphase Promoting Complex/Cyclosome Inhibitor Emi1 Leads to Tetraploidy and Genomic Instability of p53-Deficient Cells. Cell Cycle. 5(14). 1569–1573. 43 indexed citations
17.
Margottin-Goguet, Florence, et al.. (2003). Prophase Destruction of Emi1 by the SCFβTrCP/Slimb Ubiquitin Ligase Activates the Anaphase Promoting Complex to Allow Progression beyond Prometaphase. Developmental Cell. 4(6). 813–826. 284 indexed citations
18.
Hsu, Jerry Y., et al.. (2002). E2F-dependent accumulation of hEmi1 regulates S phase entry by inhibiting APCCdh1. Nature Cell Biology. 4(5). 358–366. 262 indexed citations
19.
Reimann, Julie D.R., Ellen Freed, Jerry Y. Hsu, et al.. (2001). Emi1 Is a Mitotic Regulator that Interacts with Cdc20 and Inhibits the Anaphase Promoting Complex. Cell. 105(5). 645–655. 313 indexed citations
20.
Jackson, Peter K., Adam G. Eldridge, Ellen Freed, et al.. (2000). The lore of the RINGs: substrate recognition and catalysis by ubiquitin ligases. Trends in Cell Biology. 10(10). 429–439. 532 indexed citations breakdown →

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Frauke Schimmöller Breakdown of academic impact, for papers by Grzegorz Nalepa Breakdown of academic impact, for papers by Andrew Wilber Breakdown of academic impact, for papers by Panayotis Zacharatos Breakdown of academic impact, for papers by Sylvie Giuriato Breakdown of academic impact, for papers by Tsz Kan Fung Breakdown of academic impact, for papers by Olle Sangfelt Breakdown of academic impact, for papers by Marc R. Mansour Breakdown of academic impact, for papers by Yong Wan Breakdown of academic impact, for papers by Matty Verlaan–de Vries
Rankless by CCL
2026